PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
9008610-9	1997	Interestingly, piroxicam prevented the conformational changes that beta 2 integrins underwent upon activation of neutrophils: the appearance of the activation epitope of CD11b, detected by the CBRM1/5 MAb, was blocked by piroxicam in TNF alpha-treated neutrophils.	Piroxicam	15-24	integrin subunit alpha M	Homo sapiens	170-175	
9008610-9	1997	Interestingly, piroxicam prevented the conformational changes that beta 2 integrins underwent upon activation of neutrophils: the appearance of the activation epitope of CD11b, detected by the CBRM1/5 MAb, was blocked by piroxicam in TNF alpha-treated neutrophils.	Piroxicam	221-230	integrin subunit alpha M	Homo sapiens	170-175	
9067636-4	1997	Addition of the cyclooxygenase inhibitors indomethacin (10 microM) or piroxicam (20 microM) slightly increased expression of CD11b and CD18 in cells differentiated with RA, but did not alter expression of surface antigens in cells treated with 1,25-D3.	Piroxicam	70-79	integrin subunit alpha M	Homo sapiens	125-130	
2138999-6	1990	Both piroxicam and indomethacin inhibited FMLP-induced upregulation of CD11b, CD11c, and CD35, but neither drug affected the upregulation of these surface molecules induced by C5a or ionomycin.	Piroxicam	5-14	integrin subunit alpha M	Homo sapiens	71-76	
2138999-9	1990	We conclude that piroxicam and indomethacin inhibit FMLP receptor-mediated upregulation of CD11b, CD11c, and CD35 in PMNs, but have no effect on the upregulation of these molecules by ionomycin or C5a.	Piroxicam	17-26	integrin subunit alpha M	Homo sapiens	91-96